Facebook
  1. Home
  2. Solutions
  3. Laboratories
  4. Specialty Laboratories
  5. Molecular Pathology

Molecular Pathology

Custom IHC assay development and validation

ICON specialises in custom IHC assay development and validation, offering a bespoke approach that caters to the unique needs of each clinical trial.

 

We ensure the highest standards of quality and efficiency with our CAP-accredited CLIA laboratory and advanced IHC platforms. Our comprehensive digital pathology capabilities enhance analysis precision, facilitating critical biomarker studies from clinical trials to IVD submissions. ICON empowers partners with tailored, end-to-end solutions, driving the advancement of precision medicine and improving patient outcomes.

Tailored IHC assay development and validation

ICON creates custom IHC assay development and validation strategies, catering specifically to the unique requirements of each program. This bespoke service enables retrospective and prospective analysis. Depending on the needs of a program, we can customize IHC assays for both retrospective and prospective analysis of clinical trial specimens, facilitating comprehensive biomarker studies.

State-of-the-art IHC platforms and digital pathology capabilities

To support these tailored strategies, ICON utilises an advanced array of automated IHC platforms and digital pathology tools:

Automated IHC platforms: Our suite includes the Ventana Benchmark ULTRA, Leica Bond III, Dako Omnis, and Link 48, each chosen for their capability in performing assay optimisation and running IVD assays with high precision and efficiency.

Digital pathology integration: ICON's digital pathology capabilities are cutting-edge, featuring whole-slide digital scanning (Aperio and Ventana platforms), image annotation, and web-based virtual slide review. This integration allows for detailed analysis and consultation with board-certified pathologists, enhancing the depth and accuracy of IHC assay results.

 

Your partner for precision medicine

This comprehensive approach to custom IHC assay development and validation, combined with our sophisticated IHC platforms and digital pathology capabilities, positions ICON as a leader in delivering specialised pathology services. Our focus on scientific rigor, technical excellence, and adherence to design control principles underscores our commitment to providing our partners with the insights needed to advance their clinical trials.

Through close collaboration, ICON empowers researchers and sponsors to uncover biomarker data, offering a tailored, end-to-end solution from assay development to regulatory submission. With ICON, sponsors have a partner that not only understands the complexities of IHC assays but also shares their goal of improving patient outcomes through the advancement of precision medicine.

In this section

Connect with us